Alterations of taurine in the brain of chronic kainic acid epilepsy model

Amino Acids
H Baran

Abstract

The aim of the study was to investigate the changes of taurine in the kainic acid (KA, 10 mg/kg, s.c.) chronic model of epilepsy, six months after KA application. The KA-rats used were divided into a group of animals showing weak behavioural response to KA (WDS, rare focal convulsion; rating scale <2 up to 3 h after KA injection) and a group of strong response to KA (WDS, seizures; rating >3 up to 3 h after KA injection). The brain regions investigated were caudate nucleus, substantia nigra, septum, hippocampus, amygdala/piriform cortex, and frontal, parietal, temporal and occipital cortices. KA-rats with rating <2 developed spontaneous WDS which occurred chronically and six months after KA injection increased taurine levels were found in the hippocampus (125.4% of control). KA-rats with rating >3 developed spontaneous recurrent seizures and six months after injection increased taurine levels were found in the caudate nucleus (162.5% of control) and hippocampus (126.6% of control), while reduced taurine levels were seen in the septum (78.2% of control). In summary, increased taurine levels in the hippocampus may involve processes for membrane stabilisation, thus favouring recovery after neuronal hyperactivity. The increased tau...Continue Reading

References

Mar 1, 1977·Epilepsia·N M van GelderH H Jasper
May 5, 1979·Brain Research·W J NicklasS Berl
Jan 1, 1992·Physiological Reviews·R J Huxtable
Jun 1, 1990·Molecular and Chemical Neuropathology·M C BrownJ M Pasquini
Jan 1, 1989·Progress in Neurobiology·R J Huxtable
Oct 1, 1985·Experimental Neurology·A Vezzani, R Schwarcz
Jan 1, 1986·Advances in Experimental Medicine and Biology·E D FrenchR Schwarcz
Aug 1, 1987·Journal of Neurochemistry·J V WadeT L Pazdernik
Nov 1, 1986·Journal of Neurochemistry·M PalkovitsA Patthy
Jan 1, 1974·Archives of Neurology·A Barbeau, J Donaldson
May 26, 1972·Brain Research·N M Van GelderT Rasmussen
Nov 27, 1972·Brain Research·N M Van Gelder
Mar 1, 1983·Clinical Neuropharmacology·L Durelli, R Mutani
Jan 1, 1994·Progress in Neurobiology·G Sperk
Jan 1, 1994·Progress in Neurobiology·A DepaulisC Marescaux
Jan 1, 1997·Annual Review of Pharmacology and Toxicology·P J Conn, J P Pin
Aug 12, 2003·Advances in Experimental Medicine and Biology·Abdeslem El IdrissiEkkhart Trenkner
Mar 11, 2005·Brain Research·Heng WuJang-Yen Wu
Aug 17, 2005·Current Medicinal Chemistry·R C GuptaS Bittner

❮ Previous
Next ❯

Citations

Sep 22, 2010·Journal of Basic and Clinical Physiology and Pharmacology·I StojanovićT Jevtović-Stoimenov
Feb 16, 2013·Epilepsy Research·Simo S Oja, Pirjo Saransaari
Mar 1, 2010·Environmental Toxicology and Pharmacology·Shanmugam Lakshmi Devi, Carani V Anuradha
Nov 26, 2008·Journal of Neuroscience Research·F JunyentC Auladell
Jan 19, 2010·Hippocampus·Fèlix JunyentCarme Auladell
Jun 19, 2021·Toxicology Research·Solomon E OwumiAdegboyega K Oyelere

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Amygdala: Sensory Processes

Amygdalae, nuclei clusters located in the temporal lobe of the brain, play a role in memory, emotional responses, and decision-making. Here is the latest research on sensory processes in the amygdala.

Amygdala and Midbrain Dopamine

The midbrain dopamine system is widely studied for its involvement in emotional and motivational behavior. Some of these neurons receive information from the amygdala and project throughout the cortex. When the circuit and transmission of dopamine is disrupted symptoms may present. Here is the latest research on the amygdala and midbrain dopamine.